Adjuvant immunotherapy for esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: a multicenter real-world study.

Int J Surg · 2026 · PMC12825888 · PMID 40990502

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendP = 0.09so close (0.05 < p ≤ 0.1)

The requirement for effusion treatment showed a trend toward reduction with ICI (21.8% vs. 28.2%, P = 0.09) (Supplemental Digital Content Table S2, available at, http://links.lww.com/JS9/F202 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.